Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIANO: Etravirine in HIV-1 Infected Children and Adolescents
NCT00665847Phase 2Completed
- Sponsor
- Tibotec
- Start
- Nov 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of etravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Tibotec. Primary endpoints: Number of Patients With Treatment-emergent Adverse Events at 48 weeks and Percentage of Patients With Treatment-emergent Adverse Events at 48 weeks. Started Nov 2008; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00665847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665847.